Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2015 (2015), Article ID 365205, 10 pages
Research Article

Shrinkage of Prostate and Improved Quality of Life: Management of BPH Patients with Croton membranaceus Ethanolic Root Extract

1Department of Medical Laboratory Sciences, University of Ghana School of Biomedical and Allied Health Sciences, Korle Bu, Accra, Ghana
2Ghana Police Hospital, Cantonment, Accra, Ghana
3Department of Molecular Medicine, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana
4Center for Plant Medicine Research, Mampong, Akuapem, Ghana
5Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana
6Department of Radiography, School of Biomedical and Allied Health Sciences, University of Ghana, Accra, Ghana
7Traditional and Alternative Medicine Council, Ministry of Health, Accra, Ghana

Received 17 December 2014; Revised 13 February 2015; Accepted 23 February 2015

Academic Editor: Menachem Oberbaum

Copyright © 2015 George Awuku Asare et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Benign prostatic hyperplasia (BPH) is an enlargement of the prostate. The study aimed at validating the use of freeze-dried Croton membranaceus ethanolic root extract for BPH management. Thirty-three patients were observed before and after 3-month administration of 20 mg t.i.d orally. The International Prostate Symptom Score (IPSS), and the International Index of Erectile Function (IIEF) questionnaires were used. Total/free PSA (tPSA, fPSA), renal, liver function, lipid tests, and ultrasonographic imaging were performed. Thirty (30) patients (66 ± 11 years) completed the study. IPSS results showed 37% had severe, 40% moderate, and 23% mild symptoms before; 57% and 43% had moderate and mild symptoms, respectively, after treatment. IIED of patients’ results showed 30% with severe, 40% moderate, 24% mild-moderate, 3% mild, and 3% no erectile dysfunction before treatment and 20% severe, 43% moderate, and 37% mild-moderate dysfunction, after treatment. Quality of life (QoL) improved . Significant but non-pathological increases in total and indirect bilirubin as well as apolipoprotein A occurred. Mean tPSA reduced from 27.9 ± 19.0 to 16.2 ± 11.8 ng/mL ; fPSA from 6.1 ± 4.8 to 3.9 ± 2.9 ng/mL ; and prostate volume from 101.8 ± 41.3 to 54.5 ± 24.8 cm3  . C. membranaceus shrinks the prostate and improves QoL.